Updated Results Of A Phase I/Ii Prospective Dose Escalation Trial Evaluating Safety And Efficacy Of Combination Lu-177 Psma 617 And Idronoxil In Men With Mcrpc Post Androgen Signalling Inhibition And Taxane Chemotherapy (Lupin Trial).

Louise Emmett,Sarennya Pathmanandavel,Megan Crumbaker,Christopher Rofe,Andrew On Wah Yam,Bao Ho,Wai Ling Chan,Shikha Sharma,Joanne Keane,Adam James Hickey,Karen Fullard,Kamonwan Kongrak,Lalith Ratnayake,John A. Violet,Arun Azad,Peter Eu,Andrew Nguyen,Anthony M. Joshua

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 3|浏览32

暂无评分

摘要

5557Background: There is no established standard of care post cabazitaxel in men with mCRPC. Ongoing trials in 177LuPSMA-617 have demonstrated good efficacy and safety, but synergistic combinations...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要